Lachey Jennifer
Known title: Chief Scientific OfficerCIK: 0001808322
Associated companies
Transaction History
| KROS | ▲ Buy | Option Exercise | 46,034 | $14K | 7/15/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 46,034 | $1.4M | 7/15/2022 | View on chart |
| KROS | ▲ Buy | Option Exercise | 1,916 | $575 | 7/13/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 1,916 | $57K | 7/13/2022 | View on chart |
| KROS | ▲ Buy | Option Exercise | 9,400 | $3K | 6/14/2022 | View on chart |
| KROS | ▲ Buy | Option Exercise | 5,300 | $2K | 5/11/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 944 | $40K | 5/11/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 3,398 | $140K | 5/11/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 719 | $31K | 5/11/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 223 | $10K | 5/11/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 16 | $727 | 5/11/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 1,009 | $63K | 4/11/2022 | View on chart |
| KROS | ▲ Buy | Option Exercise | 5,300 | $2K | 4/11/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 2,315 | $147K | 4/11/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 559 | $36K | 4/11/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 1,417 | $87K | 4/11/2022 | View on chart |
| KROS | ▲ Buy | Option Exercise | 7,950 | $2K | 4/4/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 7,950 | $477K | 4/4/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 875 | $48K | 3/11/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 713 | $38K | 3/11/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 1,062 | $56K | 3/11/2022 | View on chart |
| KROS | ▲ Buy | Option Exercise | 2,650 | $795 | 3/11/2022 | View on chart |
| KROS | ▲ Buy | Option Exercise | 2,650 | $795 | 2/11/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 199 | $11K | 2/11/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 1,378 | $72K | 2/11/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 1,073 | $55K | 2/11/2022 | View on chart |
| KROS | ▲ Buy | Option Exercise | 2,650 | $795 | 1/11/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 320 | $17K | 1/11/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 1,196 | $64K | 1/11/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 1,134 | $62K | 1/11/2022 | View on chart |
| KROS | ▲ Buy | Option Exercise | 2,650 | $795 | 1/5/2022 | View on chart |
| KROS | ▼ Sell | Open Market | 2,650 | $159K | 1/5/2022 | View on chart |
| KROS | ▲ Buy | Option Exercise | 735 | $221 | 12/15/2021 | View on chart |
| KROS | ▼ Sell | Open Market | 735 | $37K | 12/15/2021 | View on chart |
| KROS | ▲ Buy | Option Exercise | 1,915 | $575 | 12/13/2021 | View on chart |
| KROS | ▼ Sell | Open Market | 390 | $20K | 12/13/2021 | View on chart |
| KROS | ▼ Sell | Open Market | 7 | $375 | 12/13/2021 | View on chart |
| KROS | ▼ Sell | Open Market | 1,518 | $76K | 12/13/2021 | View on chart |
| KROS | ▲ Buy | Option Exercise | 5,300 | $2K | 11/11/2021 | View on chart |
| KROS | ▼ Sell | Open Market | 739 | $43K | 11/11/2021 | View on chart |
| KROS | ▼ Sell | Open Market | 4,561 | $273K | 11/11/2021 | View on chart |
| KROS | ▲ Buy | Option Exercise | 15,900 | $5K | 11/10/2021 | View on chart |
| KROS | ▼ Sell | Open Market | 15,900 | $954K | 11/10/2021 | View on chart |
| KROS | ▲ Buy | Option Exercise | 10,600 | $3K | 11/4/2021 | View on chart |
| KROS | ▼ Sell | Open Market | 10,600 | $530K | 11/4/2021 | View on chart |
| KROS | ▲ Buy | Option Exercise | 1,293 | $388 | 8/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Keros Therapeutics Doses First Patient in Phase 2 Rinvatercept Trial
Keros Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial evaluating rinvatercept for Duchenne Muscular Dystrophy. This milestone marks a significant step in the development of the company's lead candidate. The stock is currently trading near its support level, with analysts setting an average price target of $19.83.
Keros Therapeutics Doses First Patient in Phase 2 Rinvatercept Trial. Keros Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial evaluating rinvatercept for Duchenne Muscular Dystrophy. This milestone marks a significant step in the development of the company's lead candidate. The stock is currently trading near its support level, with analysts setting an average price target of $19.83.